- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario ; day:27 ; month:09 ; year:2023
South Asian journal of cancer ; (27.09.2023)
- Contributor
-
Shrivastva, Sarita
Bala, Stalin Chowdary
Chennamaneni, Rachana
Konatam, Meher Lakshmi
Pydi, Venkateswara Rao
Prasad, Kuruva Siva
Gundeti, Sadashivudu
- DOI
-
10.1055/s-0043-1768039
- URN
-
urn:nbn:de:101:1-2023113013332563810471
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shrivastva, Sarita
- Bala, Stalin Chowdary
- Chennamaneni, Rachana
- Konatam, Meher Lakshmi
- Pydi, Venkateswara Rao
- Prasad, Kuruva Siva
- Gundeti, Sadashivudu
Other Objects (12)
High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning
Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning
Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning